Gridai Technologies Quick Ratio (GRDX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Gridai Technologies Corp  (NASDAQ: GRDX)

Gridai Technologies's Quick Ratio

GRDX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Gridai Technologies's Cash & cash equivalent grew by 257.87 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Gridai Technologies's Quick Ratio to 0.1, Quick Ratio remained below Gridai Technologies Corp average.

Within Major Pharmaceutical Preparations industry 423 other companies have achieved higher Quick Ratio than Gridai Technologies in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 3724, from total ranking in the first quarter 2026 at 3980.

Explain Quick Ratio?
How much Cash & cash equivalents GRDX´s has?
What are GRDX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GRDX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -52.33 % -43.52 % -44.97 % 134.02 % 117.14 %
Y / Y Cash & cash equivalent Change 30738.65 % 549.59 % 450.41 % 586.26 % -99.32 %
Quick Ratio MRQ 0.1 0.02 0.06 0.08 0
GRDX's Total Ranking # 3724 # 3980 # 4130 # 0 #
Seq. Current Liabilities Change -12.85 % 7.07 % -54.77 % 12.94 % 3.26 %
Seq. Cash & cash equivalent Change 257.87 % -57.15 % -64.25 % 56163.25 % -92.46 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 424
Healthcare Sector # 853
Overall Market # 3724


Quick Ratio Statistics
High Average Low
5.19 0.73 0
(Mar 31 2021)   (Jun 30 2025)




Financial Statements
Gridai Technologies's Current Liabilities $ 14 Millions Visit GRDX's Balance sheet
Gridai Technologies's Cash & cash equivalent $ 1 Millions Visit GRDX's Balance sheet
Source of GRDX's Sales Visit GRDX's Sales by Geography


Cumulative Gridai Technologies's Quick Ratio

GRDX's Quick Ratio for the trailling 12 Months

GRDX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -21.17 % 12.23 % 80.84 % 243.26 % 348.42 %
Y / Y Cash & cash equivalent TTM Growth 772.29 % 204.05 % -24.73 % -66.42 % -94.65 %
Quick Ratio TTM 0.07 0.04 0.03 0.02 0.01
Total Ranking TTM # 4176 # 3992 # 0 # 0 #
Seq. Current Liabilities TTM Growth -16.42 % -11.68 % -10.37 % 19.14 % 19 %
Seq. Cash & cash equivalent TTM Growth 36.12 % 9.37 % 26.83 % 361.96 % -52.55 %

Quick ratio ranking by company, industry and sector >> Back to GRDX Financial Strength Comparisons >> Go to Compare GRDX Quick Ratio to its Competitors

On the trailing twelve months basis GRDX Cash & cash equivalent more than doubled by 30738.65 % in Q2 2026 year on year, while Current Liabilities fell to $14 millions, this led to increase in in Gridai Technologies's Quick Ratio to 0.07, Quick Ratio remained below GRDX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 445 other companies have achieved higher Quick Ratio than Gridai Technologies. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3992 to 4176.

Explain Quick Ratio?
How much Cash & cash equivalents GRDX´s has?
What are GRDX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 446
Healthcare Sector # 918
Within the Market # 4176


trailing twelve months Quick Ratio Statistics
High Average Low
1.39 0.52 0.01
(Sep 30 2018)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Vireo Growth Inc.  0.27 $ 104.100  Millions$ 390.700  Millions
Phibro Animal Health Corporation  0.26 $ 81.994  Millions$ 316.468  Millions
Merck and Co Inc   0.26 $ 7,141.000  Millions$ 27,731.000  Millions
Indivior Pharmaceuticals Inc   0.26 $ 222.000  Millions$ 868.000  Millions
Propanc Biopharma Inc   0.25 $ 0.832  Millions$ 3.354  Millions
Teva Pharmaceutical Industries Limited  0.23 $ 3,655.000  Millions$ 15,646.000  Millions
Cytodyn inc   0.22 $ 11.852  Millions$ 53.727  Millions
Collegium Pharmaceutical Inc   0.22 $ 129.467  Millions$ 589.861  Millions
International Stem Cell Corporation  0.22 $ 1.089  Millions$ 4.984  Millions
Earth Science Tech Inc   0.22 $ 0.631  Millions$ 2.902  Millions
Viatris Inc   0.22 $ 1,368.700  Millions$ 6,345.800  Millions
Eli Lilly And Company  0.19 $ 8,950.000  Millions$ 47,741.000  Millions
Polomar Health Services, Inc.  0.18 $ 0.188  Millions$ 1.063  Millions
Tempest Therapeutics Inc   0.18 $ 0.779  Millions$ 4.450  Millions
Abbvie Inc   0.16 $ 6,569.000  Millions$ 41,642.000  Millions
Amneal Pharmaceuticals Inc   0.15 $ 136.280  Millions$ 883.187  Millions
Neonc Technologies Holdings Inc   0.15 $ 3.573  Millions$ 23.507  Millions
Jaguar Health Inc   0.15 $ 3.788  Millions$ 25.380  Millions
Alaunos Therapeutics Inc   0.14 $ 0.124  Millions$ 0.864  Millions
Cumberland Pharmaceuticals Inc   0.11 $ 3.862  Millions$ 35.193  Millions
Igc Pharma Inc   0.11 $ 0.354  Millions$ 3.287  Millions
Tuhura Biosciences Inc   0.11 $ 0.996  Millions$ 9.255  Millions
Gridai Technologies Corp  0.10 $ 1.380  Millions$ 14.146  Millions
Bioxcel Therapeutics Inc   0.09 $ 12.841  Millions$ 137.149  Millions
Galectin Therapeutics Inc   0.09 $ 13.275  Millions$ 151.619  Millions
Lftd Partners Inc   0.08 $ 0.304  Millions$ 3.648  Millions
Processa Pharmaceuticals Inc   0.08 $ 0.196  Millions$ 2.387  Millions
Cv Sciences Inc   0.05 $ 0.266  Millions$ 4.943  Millions
Citius Pharmaceuticals Inc   0.05 $ 17.008  Millions$ 333.952  Millions
Sunshine Biopharma Inc   0.05 $ 0.281  Millions$ 5.619  Millions

Date modified: 2026-09-08T17:58:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.